COMPERA study for lung vessel pressure medicines
Part of Genetic & congenital, Heart & circulation, Lungs & breathing clinical trials.
This study follows people with different types of high blood pressure in the lungs (pulmonary hypertension) to see how starting specific lung blood vessel medicines affects outcomes. It may help improve how clinicians choose and monitor treatment over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of pulmonary hypertension (high blood pressure in the lungs)
- Your type of pulmonary hypertension fits one of these: PAH, CTEPH, PH from left-heart disease, PH from lung disease, or certain post-surgery/Fontan-related cases
- You recently started one of these medicines (or a combination) within the last 3 months: endothelin receptor blockers, PDE-5 inhibitors, sGC stimulators, or prostacyclins
- You (or your legal guardian) can sign written informed consent
- You have not been on the same class of lung pressure medicines for more than 3 months before joining (there are key exceptions for some PAH-CHD cases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called treprostinil to see if it is safe and effective for people with intermediate-risk pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. If you join, you may receive the study drug along with your usual PAH medications, which could help improve your symptoms and slow the disease.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This study looks at how environmental factors (like pollutants and lifestyle) may affect pulmonary hypertension. You will fill out questionnaires and provide a small hair sample to help understand these exposures.
This trial tests a new combination of three medicines (including an experimental drug called sotatercept) for people recently diagnosed with PAH. The goal is to see if this early, powerful treatment works better than standard care in improving heart and lung function.
This study is a registry that collects information on people with pulmonary hypertension who are using or starting targeted medications. The goal is to understand how these treatments work in real-world settings and improve care for patients like you.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.